Prognostic association of medication trajectories with 3-year mortality in heart failure and preserved ejection fraction: findings from the EPICAL2 cohort study
- 10 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 77 (10), 1569-1581
- https://doi.org/10.1007/s00228-021-03153-6
Abstract
Purpose The aims of this study were to describe combinations of beta-blockers (BB), renin-angiotensin system (RAS) blockers, and mineralocorticoid receptor antagonist (MRA) prescriptions and their trajectories in heart failure with preserved ejection fraction (HFpEF) patients, and to assess their effect on the three-year all-cause and cardiovascular (CV)-mortality. Methods We used data from the EPICAL2 cohort of 689 hospitalized HFpEF patients. Medication prescriptions were collected at hospital discharge and at 6, 12, and 24 months after discharge. A multi-trajectory approach was used to conjointly model groups of individuals following similar trajectories over medications prescriptions. We used Cox and Fine‐Gray models, to evaluate respectively the associations between 3-year all‐cause mortality and CV-mortality and the trajectory groups. Results Multi-trajectory modelling revealed five distinct trajectory groups: group1 (N = 232, 33.6%) stable ACEI/ARB and BB prescriptions, group 2 (N = 199, 28.8%) stable ACEI/ARB prescription, group 3 (N = 133, 19.3%) stable BB prescriptions, group 4 (N = 78, 11.3%) stable prescriptions of none of the medications, and group 5 (N = 47, 6.8%) stable ACEI/ARB, BB, and MRA prescriptions. As compared to the group 4 of patients receiving none of the three medications, patients receiving a stable prescription of one or a combination of two or the three medications over 2 years) had a lower overall mortality over 3-year follow-up, i.e., group 1 (HR = 0.5, 95% CI 0.4–0.8), group 2 (HR = 0.6, 95% CI:0.4–0.8), group 3 (HR = 0.5, 95% CI:0.4–0.7), and group 5 (HR = 0.5, 95% CI:0.3–0.9). However, none of these trajectory groups was associated with a lower CV-mortality over 3 years. Conclusion In an unselected population-based sample of HFpEF patients, the long-term stable use of the combination ACEI/ARB and BB, BB exclusively, ACEI/ARB exclusively, or the combination ACEI/ARB and BB and MRAs was associated with reduced three-year all-cause mortality.Keywords
Funding Information
- National Hospital program of clinical research (ANR-15-RHUS-0004)
This publication has 46 references indexed in Scilit:
- Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection FractionCirculation, 2012
- Group-Based Trajectory Modeling in Clinical ResearchAnnual Review of Clinical Psychology, 2010
- The Sympathetic Nervous System in Heart Failure: Physiology, Pathophysiology, and Clinical ImplicationsJournal of the American College of Cardiology, 2009
- Clinical Effectiveness of Beta-Blockers in Heart Failure: Findings From the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) RegistryJournal of the American College of Cardiology, 2009
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- Immortal Time Bias in PharmacoepidemiologyAmerican Journal of Epidemiology, 2007
- The perindopril in elderly people with chronic heart failure (PEP-CHF) studyEuropean Heart Journal, 2006
- Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection FractionThe New England Journal of Medicine, 2006
- A SAS Procedure Based on Mixture Models for Estimating Developmental TrajectoriesSociological Methods & Research, 2001
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987